A Randomized, Double-Blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting - Related Studies

A Randomized, Double-Blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

This study is currently recruiting participants.

Study NCT00659737. Last updated on June 9, 2008. Information provided by Drexel University

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Nausea
		Vomiting

2	Additional conditions recognized in this trial
		Postoperative Nausea and Vomiting

3	More general conditions related to this trial
		Pathologic Processes
		Postoperative Complications
		Signs and Symptoms
		Signs and Symptoms, Digestive

4	Interventions listed in this trial
		Emend (Aprepitant) + Placebo
		Scopolamine + Emend (Aprepitant)

5	Additional drug interventions recognized in this trial
		Aprepitant
		Butylscopolammonium Bromide
		Scopolamine

6	More general drug interventions related to this trial
		Adjuvants, Anesthesia
		Antiemetics
		Autonomic Agents
		Central Nervous System Agents
		Cholinergic Agents
		Cholinergic Antagonists
		Gastrointestinal Agents
		Molecular Mechanisms of Pharmacological Action
		Muscarinic Antagonists
		Mydriatics
		Neurotransmitter Agents
		Parasympatholytics
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Drexel University
		Merck